Mesintel Therapeutics has developed a proprietary target discovery platform that utilizes single-cell multi-omics and genetically engineered models to decode fibroblast biology. This platform identifies therapeutic targets for conditions like cancer and fibrosis, addressing the critical need for effective treatments in these areas.
Funding
Funding not disclosed
Founders
Product
Problem
Fibroblast dysfunction plays a significant role in numerous diseases, including cancer and fibrosis, creating a need for effective therapeutic interventions. Current methods for identifying therapeutic targets in these conditions often lack the precision and comprehensive understanding of fibroblast biology needed for successful drug development.
Solution
Mesintel Therapeutics is developing therapeutics by decoding fibroblast biology through a proprietary target discovery platform. The platform utilizes single-cell multi-omics, human disease-informed genetically engineered models, cellular lineage tracing, functional genomics, and AI/ML to identify innovative therapeutic targets. This approach allows for modifying fibroblast activity to affect health and disease, addressing unmet medical needs in areas such as cancer, fibrosis, rare diseases, tissue regeneration, and aging. The company's discovery engine yields insights into the mechanisms underlying fibroblast dysfunction.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing therapeutics for cancer, fibrosis, rare diseases, tissue regeneration, and aging.
Features
- Single-cell multi-omics analysis for comprehensive fibroblast profiling
- Human disease-informed genetically engineered models to mimic disease states
- Cellular lineage tracing to understand fibroblast development and differentiation
- Functional genomics to identify key regulators of fibroblast activity
- AI/ML-driven computational approaches for target identification and validation